Denmark Breast Cancer Drugs Market Size & Outlook, 2023-2030

The breast cancer drugs in Denmark is expected to reach a projected revenue of US$ 76.7 million by 2030. A compound annual growth rate of 7% is expected of Denmark breast cancer drugs from 2024 to 2030.
Revenue, 2023 (US$M)
$47.6
Forecast, 2030 (US$M)
$76.7
CAGR, 2024 - 2030
7.1%
Report Coverage
Denmark

Denmark breast cancer drugs highlights

  • The Denmark breast cancer drugs generated a revenue of USD 47.6 million in 2023 and is expected to reach USD 76.7 million by 2030.
  • The Denmark market is expected to grow at a CAGR of 7% from 2024 to 2030.
  • In terms of segment, targeted therapy was the largest revenue generating therapy in 2023.
  • Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.


Breast cancer drugs data book summary

Market revenue in 2023USD 47.6 million
Market revenue in 2030USD 76.7 million
Growth rate7% (CAGR from 2023 to 2030)
Largest segmentTargeted therapy
Fastest growing segmentImmunotherapy
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationChemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy
Key market players worldwideNovartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Celgene, Roche Holding AG, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc, Sanofi SA, Amgen Inc


Other key industry trends

  • In terms of revenue, Denmark accounted for 0.6% of the global breast cancer drugs in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany breast cancer drugs is projected to lead the regional market in terms of revenue in 2030.
  • Denmark is the fastest growing regional market in Europe and is projected to reach USD 76.7 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Breast Cancer Drugs Scope

Breast cancer drugs segmentation & scope
Chemotherapy
Immunotherapy
Abemaciclib
Ado-Trastuzumab Emtansine
Everolimus
Trastuzumab
Ribociclib
Palbociclib
Pertuzumab
Olaparib
Others Target Therapy
Selective Estrogen Receptor Modulators (SERMs)
Aromatase Inhibitors
Estrogen Receptor Down regulators (ERDs)
Hormone Receptor
HER2+
Hospital Pharmacies
Retail Pharmacies
Others Distribution Channel

Breast Cancer Drugs Companies

Name Profile # Employees HQ Website

Denmark breast cancer drugs outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer drugs will help companies and investors design strategic landscapes.


Targeted therapy was the largest segment with a revenue share of 64.29% in 2023. Horizon Databook has segmented the Denmark breast cancer drugs based on chemotherapy, immunotherapy, targeted therapy, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Denmark breast cancer drugs databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Denmark breast cancer drugs databook

  • Our clientele includes a mix of breast cancer drugs companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Denmark breast cancer drugs, including forecasts for subscribers. This country databook contains high-level insights into Denmark breast cancer drugs from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Denmark breast cancer drugs market size, by therapy, 2018-2030 (US$M)

Denmark Breast Cancer Drugs Share, 2023 & 2030 (US$M)

Denmark breast cancer drugs market size, by therapy, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more